دورية أكاديمية
On variants and vaccines: The effectiveness of Covid-19 monoclonal antibody therapy during two distinct periods in the pandemic
| العنوان: | On variants and vaccines: The effectiveness of Covid-19 monoclonal antibody therapy during two distinct periods in the pandemic |
|---|---|
| المؤلفون: | Srinivasan, Vinay, Weinstein, Stacey E., Bhimani, Azra, Clemons, Nathan C., Dinolfo, Melissa, Shin, Christina S., Grier, Jacqueline, Lopez, Antonio, Braggs, Jamia, Boucher, Joni, Batiste, Quanna N., Garner, Omai B., Yang, Shangxin, Vijayan, Tara |
| المصدر: | http://lobid.org/resources/990155701200206441Test#!, 17(12):e0278394. |
| سنة النشر: | 2022 |
| المجموعة: | Publisso (ZB MED-Publikationsportal Lebenswissenschaften) |
| مصطلحات موضوعية: | COVID-19, Hospitals, Medical risk factors, Monoclonal antibodies, Vaccination and immunization, Antibody therapy, Critical care and emergency medicine, Outpatients |
| الوصف: | BACKGROUND: While Covid-19 monoclonal antibody therapies (Mab) have been available in the outpatient setting for over a year and a half, little is known about the impact of emerging variants and vaccinations on the effectiveness of Mab therapies. We sought to determine the effectiveness of Covid-19 Mab therapies during the first two waves of the pandemic in Los Angeles County and assess the impact of vaccines, variants, and other confounding factors. METHODS AND FINDINGS: We retrospectively examined records for 2209 patients of with confirmed positive molecular SARS-CoV2 test either referred for outpatient Mab therapy or receiving Mab treatment in the emergency department (ED) between December 2020 and 2021. Our primary outcome was the combined 30-day incidence of ED visit, hospitalization, or death following the date of referral. Additionally, SARS-CoV2 isolates of hospitalized patients receiving Mabs were sequenced. The primary outcome was significantly reduced with combination therapy compared to bamlanivimab or no treatment (aHR 0·60; 95% CI ·37, ·99), with greater benefit in unvaccinated, moderate-to-high-risk patients (aHR ·39; 95% CI ·20, ·77). Significant associations with the primary outcome included history of lung disease (HR 7·13; 95% CI 5·12, 9·95), immunocompromised state (HR 6·59; 95% CI 2·91–14·94), and high social vulnerability (HR 2·29, 95% CI 1·56–3·36). Two predominant variants were noted during the period of observation: the Epsilon variant and the Delta variant. CONCLUSIONS: Only select monoclonal antibody therapies significantly reduced ED visits, hospitalizations, and death due to COVID-19 during. Vaccination diminished effectiveness of Mabs. Variant data and vaccination status should be considered when assessing the benefit of novel COVID-19 treatments. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://repository.publisso.de/resource/frl:6452876Test; https://doi.org/10.1371/journal.pone.0278394Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714735Test/; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278394#sec011Test |
| DOI: | 10.1371/journal.pone.0278394 |
| DOI: | 10.1371/journal.pone.0278394#sec011 |
| الإتاحة: | https://doi.org/10.1371/journal.pone.0278394Test https://repository.publisso.de/resource/frl:6452876Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714735Test/ https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278394#sec011Test |
| حقوق: | CC BY 4.0 |
| رقم الانضمام: | edsbas.7119C050 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1371/journal.pone.0278394 |
|---|